SUBSCRIBE
SUBSCRIBE

CymaBay Therapeutics

NEWS
Business
Bay Area’s CymaBay Therapeutics CEO To Retire, Interim Leader Named
March 29, 2017
 · 
5 min read
Analysts Not Sold On Medivation’s Xtandi as Breast Cancer Drug
Biotech Beach
With Promising New Gout Treatment In Its Pipeline, 2015 Will Be Big Year For CymaBay Therapeutics
November 13, 2014
 · 
2 min read
Load More
JOBS
IN THE PRESS
Biotech Bay
CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
October 18, 2023
 · 
5 min read
Biotech Bay
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 16, 2023
October 16, 2023
 · 
2 min read
Drug Development
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
September 21, 2023
 · 
5 min read
Biotech Bay
CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference
September 15, 2023
 · 
1 min read
Biotech Bay
CymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 14, 2023
 · 
3 min read
Biotech Bay
CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants
September 11, 2023
 · 
4 min read
Biotech Bay
CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants
September 11, 2023
 · 
3 min read
Drug Development
CymaBay’s Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis
September 7, 2023
 · 
8 min read
Biotech Bay
CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023
September 6, 2023
 · 
1 min read
Biotech Bay
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 28, 2023
August 28, 2023
 · 
2 min read
Load More